Targeted screening
Targeted screening has been studied in 7 papers since 2025: 2 observational studies in people, 4 reviews; 6 in the past year. The newest paper, Oct 11, 2026: “Osteoporosis in men, an underdiagnosed condition: risk factors, diagnosis, and management of fragility fractures”.
7 papers study it5 findingsUpdated
1 new paper in 30 daysSee all 7 papers on targeted screening
At a glance
The findings reach people, from one lab or study. 3 independent labs in 2 countries.
“Established cut-off values for pTau217 reflecting amyloid pathology showed pathological levels in 10-23% of participants depending on single or double cut-offs.”
None of its findings points the other way.
- 3 independent labs in 2 countries
- Funders: Karolinska Institutet and 4 more
- 2 of 4 findings with company ties
- Humans2
- In silico1
What did studies of targeted screening find?
2Studies of targeted screening measured 2 outcomes: Cost-effectiveness and Budgetary sustainability.
Cost-effectiveness
upin humans1upin silico1
2 studies
Cost-effectiveness
upin humans1upin silico1
Targeted screening improves cost-effectiveness in silico (decision-tree model using community-based prevalence data) (Rs 7729; US$23 per additional detected AF case).
In silicodecision-tree model using community-based prevalence data1 year
Targeted screening improves cost-effectiveness in humans (compared with universal screening).
Reviewcompared with universal screening
Budgetary sustainability
upin humans1
1 study
Budgetary sustainability
upin humans1
Targeted screening improves budgetary sustainability in humans.
Reviewtargeting high-risk subgroups using nonmydriatic digital fundus photography and artificial intelligence tools
What is targeted screening linked with?
2Studies link targeted screening with 2 measures: detectable cognitive impairment and pathological pTau217 levels.
Detectable cognitive impairment
upin humans1
1 study
Detectable cognitive impairment
upin humans1
Targeted screening is associated with detectable cognitive impairment in humans (hypertension or type 2 diabetes and self-reported memory complaints) (approximately one-third).
Humanshypertension or type 2 diabetes and self-reported memory complaintsn = 40
Pathological pTau217 levels
upin humans1
1 study
Pathological pTau217 levels
upin humans1
Targeted screening is associated with pathological pTau217 levels in humans (hypertension or type 2 diabetes and self-reported memory complaints) (10-23%).
Humanshypertension or type 2 diabetes and self-reported memory complaintsn = 40
Funding
2 grants since 2020National Institute for Health Research£587KProstate Cancer Foundation
Contains public sector information licensed under the Open Government Licence v3.0.